NCT05579678 APOLLO: Personalized rehAbilitation PrOgram in aLLOgeneic Bone Marrow Transplantation
| NCT ID | NCT05579678 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alberta |
| Condition | Allogeneic Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2022-11-20 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2022-11-20 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
People who undergo allogeneic bone marrow transplant for blood cancers receive the highest chemotherapy doses possible that humans can receive and still survive. As a result, they have devastating side effects during the procedure and for many years afterwards. Damage to organs and muscles cause long-lasting physical weakness and the psychological experience is severe enough to be termed 'post traumatic stress disorder' that also lasts for many years. These effects are worsened by the fact that most Canadians live several hours away from treatment and transplant centers, leaving them entirely on their own to manage these difficult long term effects. The APOLLO team will perform a qualitative study to learn the experiences of people undergoing allogeneic bone marrow transplant while they receive access to a supportive care computer 'app' and telephone support from nursing, exercise and nutrition experts. In this way, the APOLLO team will learn the most helpful type and timing of supportive care from those who know best.
Eligibility Criteria
Inclusion Criteria: * eligible for allogeneic transplantation Exclusion Criteria: * none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05579678 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Allogeneic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05579678 currently recruiting?
Yes, NCT05579678 is actively recruiting participants. Contact the research team at pituskin@ualberta.ca for enrollment information.
Where is the NCT05579678 trial being conducted?
This trial is being conducted at Edmonton, Canada.
Who is sponsoring the NCT05579678 clinical trial?
NCT05579678 is sponsored by University of Alberta. The trial plans to enroll 45 participants.